Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

D. Geynisman · SciRah

Researcher profile · Semantic Scholar

D. Geynisman

Share profile

D. Geynisman — researcher profile on SciRah

h-index: 40
Works: 349
Citations: 5,335

Most-cited papers

Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma
A. Apolo, K. Ballman, G. Sonpavde, Stephanie Berg +36 more
2024New England Journal of Medicine138 citations Open access
Semantic Scholar
ARV-766, a proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC): Initial results of a phase 1/2 study.
D. Petrylak, M. McKean, J. M. Lang, Xin Gao +15 more
2024Journal of Clinical Oncology44 citations
Semantic Scholar
A phase 2 trial of risk enabled therapy after neoadjuvant chemotherapy for muscle-invasive bladder cancer (RETAIN 1)
D. Geynisman, P. Abbosh, E. Ross, M. Zibelman +15 more
2024Journal of Clinical Oncology42 citations Open access
Semantic Scholar
AMBASSADOR Alliance A031501: Phase III randomized adjuvant study of pembrolizumab in muscle-invasive and locally advanced urothelial carcinoma (MIUC) vs observation.
A. Apolo, K. Ballman, G. Sonpavde, S. Berg +16 more
2024Journal of Clinical Oncology38 citations
Semantic Scholar
NCCN Guidelines® Insights: Testicular Cancer, Version 2.2025.
T. Gilligan, Daniel W. Lin, N. Adra, A. Bagrodia +31 more
2025The Journal of the National Comprehensive Cancer Network33 citations
Semantic Scholar
A phase 2 trial of risk enabled therapy after neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer (RETAIN-2).
P. Ghatalia, E. Ross, M. Zibelman, F. Anari +16 more
2025Journal of Clinical Oncology27 citations Open access
Semantic Scholar
Renal cell carcinoma histologic subtypes exhibit distinct transcriptional profiles
Pedro C. Barata, Shuchi Gulati, A. Elliott, H. Hammers +15 more
2024Journal of Clinical Investigation19 citations Open access
Semantic Scholar
Endpoints for the next-generation bladder-sparing perioperative trials for patients with muscle-invasive bladder cancer
A. Necchi, M. Galsky, Nazli Dizman, D. Aggen +40 more
2025Journal of Clinical Oncology17 citations
Semantic Scholar
Final results of CORE-001: A phase-2, single arm study of cretostimogene grenadenorepvec in combination with pembrolizumab in patients with BCG-unresponsive, non-muscle invasive bladder cancer with carcinoma in situ.
Roger Li, Paras H. Shah, Tyler F. Stewart, T. Bivalacqua +9 more
2024Journal of Clinical Oncology14 citations Open access
Semantic Scholar
Circulating tumor DNA (ctDNA) to guide response-adapted bladder preservation in muscle invasive bladder cancer (MIBC): Integrated analysis of the RETAIN trials.
P. Ghatalia, E. Ross, M. Zibelman, F. Anari +16 more
2026Journal of Clinical Oncology11 citations Open access
Semantic Scholar
Bladder cancer microbiome and its association with chemoresponse
Rashida Ginwala, L. Bukavina, M. Sindhani, Erika Nachman +7 more
2025Frontiers in Oncology10 citations Open access
Semantic Scholar
Impact of postprogression therapies on overall survival: Recommendations from the 2023 kidney cancer association think tank meeting.
Stephanie A. Berg, S. La Rosa, Tian Zhang, Phillip M. Pierorazio +20 more
2024Urologic oncology9 citations Open access
Semantic Scholar
Wilms Tumor, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.
F. Balis, Daniel M. Green, Amy Armstrong, Jamie M. Aye +28 more
2025The Journal of the National Comprehensive Cancer Network8 citations
Semantic Scholar
Role of Gut Microbiome in Neoadjuvant Chemotherapy Response in Urothelial Carcinoma: A Multi-institutional Prospective Cohort Evaluation
L. Bukavina, Rashida Ginwala, M. Eltoukhi, M. Sindhani +16 more
2024Cancer Research Communications8 citations Open access
Semantic Scholar
Androgen production, uptake, and conversion (APUC) genes define prostate cancer patients with distinct clinical outcomes
Hannah E. Bergom, Ella Boytim, S. McSweeney, Negar Sadeghipour +12 more
2024JCI Insight6 citations Open access
Semantic Scholar
A phase 1/2 trial of durvalumab plus intravesical gemcitabine and docetaxel in BCG-unresponsive non-muscle invasive bladder cancer patients (HCRN GU16-243: ADAPT-BLADDER Cohort 4).
Noah M. Hahn, M. Zahurak, Hristos Z. Kaimakliotis, T. Masterson +16 more
2025Journal of Clinical Oncology5 citations Open access
Semantic Scholar
Estimating the Impact of Adjuvant Treatment With Nivolumab on Long-Term Survivorship Rates Compared With Surveillance in Muscle Invasive Urothelial Carcinoma: Mixture Cure Modeling Analyses of Disease-Free Survival From the Phase 3 CheckMate 274 Trial.
D. Geynisman, Kateryna Chepynoga, G. Yates, A. Tate +5 more
2025Clinical Genitourinary Cancer5 citations
Semantic Scholar
Developing biomarkers and methods of risk stratification: Consensus statements from the International Kidney Cancer Symposium North America 2024 Think Tank.
Daniel D. Shapiro, E. J. Abel, L. Albiges, D. Battle +36 more
2025Urologic oncology5 citations
Semantic Scholar
Urine biopsy as dynamic biomarker to enhance clinical staging of bladder cancer in radical cystectomy candidates
Uttam Satyal, Henkel Valentine, David Liu, M. Slifker +25 more
2024JCO Precision Oncology5 citations
Semantic Scholar
Molecular alteration profiles characterize intraductal carcinoma of the prostate
Harshitha Dudipala, S. Nazari, I. Werneck da Cunha, Nathan Coligado +11 more
2025Cancer4 citations
Semantic Scholar
Survival Outcomes in Patients With Muscle-Invasive Bladder Cancer Receiving Neoadjuvant Chemotherapy Stratified by Number of Cycles.
Anumita Chakraborty, J. Hasler, E. Handorf, F. Anari +5 more
2024Clinical Genitourinary Cancer4 citations
Semantic Scholar
Serious Illness Conversations and Advance Care Planning: Can Machine-Learning or AI Really Help?
D. Geynisman
2025The Journal of the National Comprehensive Cancer Network2 citations
Semantic Scholar
Treatment Patterns and Costs Among Patients With Metastatic Renal Cell Carcinoma in the United States: A Real-World Study Using Integrated Claims and Clinical Data.
D. Geynisman, Nathan R. Hill, L. Rosenblatt, Xin Yin +5 more
2025JCO Oncology Practice2 citations
Semantic Scholar
Assessing Treatment Outcomes of Patients Undergoing Enfortumab Vedotin Dose Reduction in Metastatic Bladder Cancer.
H.F. Rives, J. Fredette, F. Anari, P. Ghatalia +3 more
2026Clinical Genitourinary Cancer1 citations
Semantic Scholar
The use of an electronic medical record (EMR) best practice advisory (BPA) to facilitate oncofertility referrals and fertility preservation: Updated analysis.
A. Meeter, Disha Sawhney, Eileen S. Seltzer, D. Geynisman +1 more
2025JCO Oncology Practice1 citations Open access
Semantic Scholar
Real-world analysis of 2IR immune response score in urothelial carcinoma (UC).
Jason R. Brown, T. Adeyelu, A. Elliott, A. Basu +8 more
2025Journal of Clinical Oncology1 citations
Semantic Scholar
Real-World Outcomes of Nivolumab Plus Ipilimumab Versus Pembrolizumab Plus Axitinib for First-Line Treatment of Advanced Renal Cell Carcinoma.
D. Geynisman, W. John, Taavy A. Miller, Parisa Asgarisabet +6 more
2025Clinical Genitourinary Cancer1 citations
Semantic Scholar
Multi-omic characterization of acquired resistance to immune checkpoint inhibitors in patients with metastatic renal cell carcinoma.
E. Saad, C. Labaki, B. Miron, Jihye Park +16 more
2024Journal of Clinical Oncology1 citations Open access
Semantic Scholar
Racial differences in real-world outcomes of first-line therapies for advanced renal cell carcinoma
D. Geynisman, W. John, Taavy A. Miller, Parisa Asgarisabet +5 more
2024The Oncologist1 citations Open access
Semantic Scholar
MP14-19 ARV-766, A PROTAC ANDROGEN RECEPTOR (AR) DEGRADER, COMBINED WITH ABIRATERONE IN NOVEL HORMONAL AGENT (NHA)-NA&IUML;VE METASTATIC PROSTATE CANCER: PHASE 1 COHORT (PART C) OF A PHASE 1/2 STUDY
N. Shore, J. M. Lang, D. Geynisman, Tyler F. Stewart +10 more
2024Journal of Urology1 citations
Semantic Scholar
1964MO Alliance A031501: AMBASSADOR study of adjuvant pembrolizumab (Pembro) in muscle-invasive urothelial carcinoma (MIUC) vs observation (Obs): Extended follow-up disease-free survival (DFS) results and metastatic (met) disease recurrence distribution
A. Apolo, K. Ballman, G. Sonpavde, S. Berg +16 more
2024Annals of Oncology1 citations
Semantic Scholar
Estimating the impact of adjuvant treatment with nivolumab on long-term survivorship rates compared with surveillance: Analyses of disease-free survival (DFS) from the phase 3 CheckMate-274 trial.
D. Geynisman, G. Yates, Kateryna Chepynoga, Siguroli Teitsson +3 more
2024Journal of Clinical Oncology1 citations Open access
Semantic Scholar
Treatment patterns and costs among patients with metastatic renal cell carcinoma (mRCC) in the United States: A real-world study using integrated claims and clinical data.
D. Geynisman, Nathan R. Hill, L. Rosenblatt, Xin Yin +5 more
2024Journal of Clinical Oncology1 citations Open access
Semantic Scholar
Assessing impact of RDI on outcomes in patients treated with enfortumab vedotin-pembrolizumab combination therapy.
Lucas Antonio Viti-Guzman, J. Fredette, Joy Li, Nagendra Dhanikonda +9 more
2026Journal of Clinical Oncology0 citations
Semantic Scholar
Pathologic response after neoadjuvant therapy in renal cell carcinoma using irRVT criteria.
Benjamin J. Croll, H. A. Yahya, E. Ross, Abigail Keller +15 more
2026Journal of Clinical Oncology0 citations Open access
Semantic Scholar
The Year 2076.
D. Geynisman
2026The Journal of the National Comprehensive Cancer Network0 citations
Semantic Scholar
A New Year, A New Mind?
D. Geynisman
2026The Journal of the National Comprehensive Cancer Network0 citations
Semantic Scholar
Feasibility and Characterization of Immune-related Pathologic Response Criteria in Renal Cell Carcinoma.
Benjamin J. Croll, H. A. Yahya, J. Fredette, Abigail Keller +15 more
2026European Urology Oncology0 citations Open access
Semantic Scholar
Circulating tumor DNA analysis from the prospective pT0 study of systematic endoscopic evaluation in patients undergoing radical cystectomy for bladder cancer.
M. Zibelman, Jin-Hong Cui, D. Geynisman, P. Ghatalia +16 more
2026Journal of Clinical Oncology0 citations Open access
Semantic Scholar
IP40-12 RENAL FUNCTION PRESERVATION WITH NEOADJUVANT THERAPY IN RENAL CELL CARCINOMA PATIENTS WITH CHRONIC KIDNEY DISEASE
Benjamin J. Croll, H. A. Yahya, Abigail Keller, Rainjade Chung +13 more
2026Journal of Urology0 citations
Semantic Scholar
A phase II trial of neoadjuvant zanzalintinib (ZANZA) plus nivolumab (NIVO) in patients with locally advanced and/or surgically challenging clear cell renal cell carcinoma (EXPLORE-RCC).
Qian Qin, Song Zhang, Isamu Tachibana, Lin Lin +15 more
2026Journal of Clinical Oncology0 citations
Semantic Scholar
Curing Prostate Cancer?
D. Geynisman
2026The Journal of the National Comprehensive Cancer Network0 citations
Semantic Scholar
Clinical Outcomes of Metastatic Urothelial Carcinoma Patients Discontinuing Enfortumab Vedotin Due to Toxicity and/or Clinical Response.
Joy Li, J. Fredette, Nagendra Dhanikonda, Miraan Jhaveri +9 more
2026Clinical Genitourinary Cancer0 citations
Semantic Scholar
Advancing Clinical Trials for Rare Renal Cell Carcinoma Subtypes: Consensus Statements from the International Kidney Cancer Symposium North America 2025 Think Tank
P. Msaouel, Salvatore La Rosa, E. J. Abel, Laurence Albigès +42 more
2026Urologic oncology0 citations Open access
Semantic Scholar
Induction enfortumab vedotin plus pembrolizumab followed by maintenance pembrolizumab in first-line metastatic urothelial carcinoma (IMPROEV).
P. Ghatalia, E. Ross, Suzanne Cole, Jacqueline T. Brown +6 more
2026Journal of Clinical Oncology0 citations Open access
Semantic Scholar
Response-Adapted Bladder Preservation in Muscle-Invasive Bladder Cancer: Results of the Phase II RETAIN-2 Trial and Analysis of ctDNA Dynamics
P. Ghatalia, E. Ross, L. Zhang, A. W. Macfarlane +25 more
2026medRxiv0 citations Open access
Semantic Scholar
Feasibility and acceptability of FinCare: A personalized online tool for estimating out-of-pocket costs for cancer treatment
Carolyn Y. Fang, Amani Boudriga, Amine Raounak, Howard Isenstein +5 more
2026Digital Health0 citations Open access
Semantic Scholar
IP84-18 MARKERS OF SYSTEMIC IMMUNE ACTIVATION DO NOT PREDICT TUMOR RESPONSE BASED ON IMMUNE RELATED RESIDUAL VIABLE TUMOR (%IRRVT)
Benjamin J. Croll, H. A. Yahya, Abigail Keller, Rainjade Chung +13 more
2026Journal of Urology0 citations
Semantic Scholar
Re: Perioperative Apalutamide in High-risk Localized Prostate Cancer.
G. Hemenway, D. Geynisman
2026European Urology0 citations
Semantic Scholar
Prevalence of PD-L1-High Tumor Expression and Association with First-Line Treatment Outcomes in Patients with Metastatic Urothelial Carcinoma: Results from a Prospective Observational Cohort Study.
P. Grivas, P. Agarwal, H. Al-Ahmadie, Terence W. Friedlander +8 more
2026Targeted oncology0 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

M. Zibelman×18
Invite
M. Zibelman — researcher profile on SciRah
P. Ghatalia×16
Invite
P. Ghatalia — researcher profile on SciRah
E. Plimack×14
Invite
E. Plimack — researcher profile on SciRah
F. Anari×13
Invite
F. Anari — researcher profile on SciRah

×9

Invite

R. Viterbo — researcher profile on SciRah

Invite

M. Smaldone — researcher profile on SciRah

Invite

E. Ross — researcher profile on SciRah

Invite

P. Grivas — researcher profile on SciRah

Invite

P. Abbosh — researcher profile on SciRah

Invite

R. Uzzo — researcher profile on SciRah

Invite

A. Kutikov — researcher profile on SciRah

Invite

A. Kutikov — researcher profile on SciRah